SK Biopharmaceuticals Co., Ltd. 326030

Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO’s Type 2 LRRK2/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 — 1ST Biotherapeutics, Inc. (“1STBIO”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance 1

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.

Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.

On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines […]

It signed a collaboration and licensing deal potentially worth $795 million.

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.

Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim.

Biohaven Ltd. (NYSE:BHVN) shares gained 7% on Wednesday after the biotechnology company announced a strategic global licensing agreement with SK Biopharmaceuticals covering its Kv7 ion channel platform and epilepsy candidate opakalim.

Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.

SK Biopharmaceuticals Co., Ltd. (www.skbp.com/ CEO: Donghoon Lee) held a press conference on August 26th and announced that it has entered into an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven").

Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and SK Biopharmaceuticals Co., Ltd. ("SK Biopharmaceuticals") today announced a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy, with RISE3 trial topline result

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of focal seizures in adults. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2027.

Named SK Life Science LinX, the roughly 530sqm facility is located within the company's US subsidiary, SK Life Science, and includes shared workspace, ten private offices and conference rooms.

Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life's strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, as well as other renowned shareho

SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., today announced that it will present multiple posters at the American Academy of Neurology (AAN)Annual Meeting, taking place April 18–22, 2026, in Chicago, Illinois.

SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufacturing, and commercialization of WARF's "WT-7695," a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the Uni

As National Epilepsy Awareness Month begins on Saturday, new survey findings from SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the way of proper care and important treatment decisions. Notably, nearly three-quarters of people living with epilepsy report they don't share all seizures with their doctors, undersco